M. Underwood

发表

S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor

E. Garvey, S. Foster, T. Fujiwara, 2009 .

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

A. Lazzarin, M. Clementi, R. Burioni, 2013, The Journal of antimicrobial chemotherapy.

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.

E. Garvey, T. Seki, S. Foster, 2008, Antiviral research.

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.

E. Garvey, T. Seki, S. Foster, 2009, Antiviral research.

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

T. Seki, K. Weaver, F. Deanda, 2011, Antimicrobial Agents and Chemotherapy.

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.

Kimberly Smith, M. Aboud, R. Kaplan, 2019, The Lancet. Infectious diseases.

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection

J. Rockstroh, P. Cahn, A. Antinori, 2021, AIDS.

In Vitro Activities of Benzimidazole d- and l-Ribonucleosides against Herpesviruses

E. Kern, Nicole L. Kushner, L. Townsend, 2003, Antimicrobial Agents and Chemotherapy.

Inhibition of Human Cytomegalovirus DNA Maturation by a Benzimidazole Ribonucleoside Is Mediated through the UL89 Gene Product

L. Townsend, J. Drach, S. Stanat, 1998, Journal of Virology.

Mechanism of Action of the Ribopyranoside Benzimidazole GW275175X against Human Cytomegalovirus

R. Ferris, L. Townsend, J. Drach, 2004, Antimicrobial Agents and Chemotherapy.

Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review

J. Gatell, M. Aboud, V. Vannappagari, 2019, Antiviral therapy.

Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study

J. Gatell, Kimberly Smith, M. Aboud, 2019, Journal of Infection and Public Health.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

The Cys607→Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients

F. Baldanti, G. Gerna, A. Sarasini, 1998, Antimicrobial Agents and Chemotherapy.

Identification of Peptides That Inhibit the DNA Binding, trans-Activator, and DNA Replication Functions of the Human Papillomavirus Type 11 E2 Protein

K. Pearce, W. Rocque, E. Garvey, 2004, Journal of Virology.

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens

D. Gibb, D. Irlbeck, M. Ait-Khaled, 2004, HIV medicine.

Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS

F. Baldanti, S. Chou, G. Gerna, 1996, Journal of virology.

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

N. Parkin, D. Irlbeck, L. Trinh, 2009, The Journal of infectious diseases.

Differences in DNA Packaging Genes and Sensitivity to Benzimidazole Ribonucleosides between Human Cytomegalovirus Strains AD169 and Towne

R. Ptak, P. Krosky, L. Townsend, 2000, Antiviral chemistry & chemotherapy.

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

A. Zolopa, M. Ramgopal, Tulika Singh, 2021, AIDS.

Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

J. Rockstroh, P. Cahn, A. Antinori, 2020, Journal of Infection and Public Health.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics

Kazunari Hattori, R. Nolte, T. Yoshinaga, 2013, PloS one.

In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

Shigeru Miki, Akihiko Sato, Kevin W. Brown, 2010, Antimicrobial Agents and Chemotherapy.

Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection

E. Garvey, T. Seki, T. Fujiwara, 2014, Antimicrobial Agents and Chemotherapy.

The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral

E. Garvey, S. Foster, T. Fujiwara, 2007, Antimicrobial Agents and Chemotherapy.

Resistance of Human Cytomegalovirus to Benzimidazole Ribonucleosides Maps to Two Open Reading Frames: UL89 and UL56

R. Ptak, P. Krosky, L. Townsend, 1998, Journal of Virology.

Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine Susceptibility

C. Chappey, N. Parkin, L. Ross, 2006, Journal of acquired immune deficiency syndromes.

Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease.

L. Frick, J. Chulay, J. Drach, 1999, Advances in experimental medicine and biology.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

C. Hung, F. Castelli, M. Aboud, 2018, The Lancet.

Novel secondary mutations C56S and G149A confer resistance to HIV‐1 integrase strand transfer inhibitors

T. Seki, T. Miyamoto, T. Fujiwara, 2018, Antiviral research.

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

S. Piscitelli, T. Fujiwara, T. Hawkins, 2011, AIDS.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

P. Cahn, M. Ramgopal, A. Pozniak, 2013, The Lancet.

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

M. Wainberg, T. Fujiwara, P. Quashie, 2011, Journal of Virology.

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Keith Nangle, Kimberly Smith, M. Aboud, 2021, Antimicrobial agents and chemotherapy.

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance

A. Zolopa, J. Demarest, M. S. St. Clair, 2018, AIDS research and human retroviruses.

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

D. Podzamczer, C. Orkin, Kimberly Smith, 2019, The lancet. HIV.

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

J. Rockstroh, P. Cahn, A. Antinori, 2019, Journal of acquired immune deficiency syndromes.

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies

C. Hung, J. Slim, J. Eron, 2019, Journal of Infection and Public Health.

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies

Kimberly Smith, B. Wynne, A. Tenorio, 2019, Open Forum Infectious Diseases.

Open Reading Frames: UL89 and UL56 Benzimidazole Ribonucleosides Maps to Two Resistance of Human Cytomegalovirus to

R. Ptak, L. Townsend, J. Westerman, 2013 .

Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance In Vitro

T. Seki, T. Fujiwara, T. Yoshinaga, 2015, Antimicrobial Agents and Chemotherapy.

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

Jeffrey N. Martin, S. Deeks, T. Fujiwara, 2012, Journal of acquired immune deficiency syndromes.

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.

C. Hung, J. Slim, J. Eron, 2020, Journal of acquired immune deficiency syndromes.

Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and -2 Randomized Clinical Trials.

C. Orkin, Kimberly Smith, B. Wynne, 2020, Journal of acquired immune deficiency syndromes.

Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies

B. Wynne, R. Mehta, H. Crauwels, 2023, British journal of clinical pharmacology.

Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572)

F. Deanda, Joseph H Horton, A. Sato, 2013, Antimicrobial Agents and Chemotherapy.

Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance In Vitro

T. Seki, T. Fujiwara, T. Yoshinaga, 2015, Antimicrobial Agents and Chemotherapy.

Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness

M. Wainberg, T. Seki, P. Quashie, 2012 .